Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland. The company's lead pivotal-stage product candidate, Eptinezumab, a monoclonal antibody inhibiting calcitonin gene-related peptide, which is in Phase III pivotal trials for the prevention of migraine. Its product candidate pipeline also includes ALD1910, a preclinical monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38; and Clazakizumab, that has completed two Phase 2b clinical trials designed to block the pro-inflammatory cytokine IL-6. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDR
Previous Symbol
CUSIPN/A
Phone425-205-2900
Debt
Debt-to-Equity Ratio0.97
Current Ratio15.34
Quick Ratio15.34
Price-To-Earnings
Trailing P/E Ratio-2.31
Forward P/E Ratio-2.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.62 million
Price / Sales482.11
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.12 per share
Price / Book2.77
Profitability
EPS (Most Recent Fiscal Year)($4.95)
Net Income$-288,870,000.00
Net MarginsN/A
Return on Equity-107.70%
Return on Assets-55.60%
Miscellaneous
Employees193
Outstanding Shares68,330,000
Market Cap$808.30 million
OptionableOptionable
Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions
What is Alder Biopharmaceuticals' stock symbol?
Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder Biopharmaceuticals' earnings last quarter?
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) announced its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.13) by $0.22. View Alder Biopharmaceuticals' Earnings History.
When is Alder Biopharmaceuticals' next earnings date?
What price target have analysts set for ALDR?
13 analysts have issued twelve-month price objectives for Alder Biopharmaceuticals' stock. Their predictions range from $15.00 to $30.00. On average, they anticipate Alder Biopharmaceuticals' share price to reach $22.0909 in the next twelve months. This suggests a possible upside of 93.3% from the stock's current price. View Analyst Price Targets for Alder Biopharmaceuticals.
What is the consensus analysts' recommendation for Alder Biopharmaceuticals?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alder Biopharmaceuticals.
What are Wall Street analysts saying about Alder Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (11/12/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and $21 PT for ALDR. Monday, AMC, Alder reported cash of $485M, and our model projects the balance sheet to fund operations well into 2020. Questions on the earnings call centered on the eptinezumab market opportunity and commercialization strategy as the fourth CGRP monoclonal to enter the space. We believe that epti’ is in a class all its own as the only IV form and has a differentiated clinical profile that makes it well-positioned to target the highest burden migraine market and a prescriber base that would prefer to use in-office infusion capabilities." (11/6/2018)
- 3. Canaccord Genuity analysts commented, "We would BUY ALDR on this AGN-related dip Earlier today (6/11), Allergan (AGN, not covered) released top-line Phase 2b/3 data on atogepant, which is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that is in development for the prevention of migraine. These early top-line data bode well for AGN and BHVN’s oral migraine-prevention products; see here for our note on BHVN ($36.11 | BUY, $40 price target). In short, however, we view ALDR’s intravenous (IV) eptinezumab as sufficiently differentiated vs. other injectables that are all subcutaneous, and orals that are much farther behind and do not have as much safety/efficacy data as injectables currently. As such, we believe eptinezumab has a significant role to play in migraine prevention especially for patients with chronic migraine, which is defined as >15 episodes per month for clinical trial purposes." (6/13/2018)
Has Alder Biopharmaceuticals been receiving favorable news coverage?
Headlines about ALDR stock have been trending somewhat positive on Tuesday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alder Biopharmaceuticals earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Alder Biopharmaceuticals' key competitors?
Some companies that are related to Alder Biopharmaceuticals include FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK), Endo International (ENDP), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT) and Xencor (XNCR).
Who are Alder Biopharmaceuticals' key executives?
Alder Biopharmaceuticals' management team includes the folowing people:
- Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 58)
- Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 57)
- Ms. Elisabeth A. Sandoval M.B.A., M.B.A, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 56)
- Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 58)
- Mr. Robert W. Azelby, Pres, CEO & Director (Age 50)
Who are Alder Biopharmaceuticals' major shareholders?
Alder Biopharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.54%), Foresite Capital Management II LLC (2.32%), Brown Advisory Inc. (1.65%), TIAA CREF Investment Management LLC (1.54%), Foresite Capital Management IV LLC (1.46%) and Pinnacle Associates Ltd. (1.44%). Company insiders that own Alder Biopharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton and Stephen M Dow. View Institutional Ownership Trends for Alder Biopharmaceuticals.
Which institutional investors are selling Alder Biopharmaceuticals stock?
ALDR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Pinnacle Associates Ltd., Foresite Capital Management II LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Rhumbline Advisers and Virginia Retirement Systems ET AL. Company insiders that have sold Alder Biopharmaceuticals company stock in the last year include Jeffrey T L Smith, John A Latham and Mark James Litton. View Insider Buying and Selling for Alder Biopharmaceuticals.
Which institutional investors are buying Alder Biopharmaceuticals stock?
ALDR stock was acquired by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Man Group plc, Foresite Capital Management IV LLC, First Trust Advisors LP, Fosun International Ltd, Bellevue Group AG, Vanguard Group Inc. and Mutual of America Capital Management LLC. View Insider Buying and Selling for Alder Biopharmaceuticals.
How do I buy shares of Alder Biopharmaceuticals?
Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alder Biopharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $11.43.
How big of a company is Alder Biopharmaceuticals?
Alder Biopharmaceuticals has a market capitalization of $808.30 million and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-288,870,000.00 in net income (profit) each year or ($4.95) on an earnings per share basis. Alder Biopharmaceuticals employs 193 workers across the globe.
What is Alder Biopharmaceuticals' official website?
How can I contact Alder Biopharmaceuticals?
Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]
MarketBeat Community Rating for Alder Biopharmaceuticals (NASDAQ ALDR)
MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
